Showing results (71-80 of 80) with videos related to
Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Hemasphere|July 10, 2023
Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER TrialGerhard Held, Lorenz Thurner, Viola Poeschel, et al.Journal of Cancer Research and Clinical Oncology|September 28, 2022
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registryMaher Hanoun, Leo Ruhnke, Michael Kramer, et al.British Journal of Cancer|August 4, 2023
Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experienceJulius C Enßle, Sebastian Wolf, Sebastian Scheich, et al.Haematologica|February 23, 2023
Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemiaSabine Kayser, David Martínez-Cuadrón, Rebeca Rodriguez-Veiga, et al.Trials|November 4, 2021
Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AMLSonia Jaramillo, Johannes Krisam, Lucian Le Cornet, et al.Blood|December 20, 2018
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with <i>FLT3</i>-ITDRichard F Schlenk, Daniela Weber, Walter Fiedler, et al.Lancet (London, England)|December 24, 2019
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trialViola Poeschel, Gerhard Held, Marita Ziepert, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2024
Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance LeukemiaChristoph Röllig, Björn Steffen, Christoph Schliemann, et al.Hemasphere|July 10, 2023
Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER StudyLorenz Thurner, Marita Ziepert, Christian Berdel, et al.American Journal of Hematology|January 6, 2026
Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction TherapyStefan Markus Dendorfer, Katharina Schmidt-Brücken, Michael Kramer, et al.Pageof 8